### Human AGER Protein

#### Cat. No. AER-HM101

# ĸvoins

Description	
Source	Recombinant Human AGER Protein is expressed from HEK293 with His tag at the C-Terminus.
	It contains Ala23- Ala344.
Accession	Q15109-1
Molecular Weight	The protein has a predicted MW of 35.3 kDa. Due to glycosylation, the protein migrates to 50-60 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1EU per µg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC
Formulation and Storage	
Formulation	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt80°C for 3-6 months after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Background	
	The receptor for advanced glycation end products (AGER) is an oncogenic transmembranous receptor up- regulated in various human cancers. AGER promotes proliferation, migration, and inhibits apoptosis of squamous cervical cancer and might function as a tumor promoter in cervical cancer. Our study provides novel evidence for a potential role of AGER in bridging human papillomavirus (HPV)-induced inflammation and cervical cancer.

#### Assay Data

#### **Bis-Tris PAGE**



Human AGER on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

#### SEC-HPLC



Cat. No. AER-HM101

## Assay Data





The purity of Human AGER is greater than 95% as determined by SEC-HPLC.